Previous 10 | Next 10 |
2023-04-15 05:39:00 ET Cathie Wood's flagship exchange-traded fund, the ARK Innovation ETF, is trouncing the S&P 500 this year with a 20.5% gain versus just 6.6% for the benchmark index. Despite a big run-up to start 2023, Cathie Wood and Ark Invest think some of their favor...
Exact Sciences Presents Advancements in Cancer Detection at American Association for Cancer Research® 2023 Annual Meeting PR Newswire Research from Exact Sciences' multi-cancer early detection (MCED) program supports advanced imaging as an optimal and potentially more e...
Exact Sciences schedules first quarter 2023 earnings call PR Newswire MADISON, Wis. , April 10, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to releas...
2023-04-06 02:30:11 ET Summary Population-based cancer screening is now closer than ever to becoming a reality. EXAS products have a leading market position in their respective markets, offering a solid foundation as the company expands into new market opportunities. Q4 delive...
2023-04-04 08:50:21 ET Summary MDxHealth has 4 validated testing products with one more in the clinical pipeline. All are focused specifically on urology. The company expects to do ~$65-$70M of sales in 2023, but the valuation is a paltry $88M. The total addressable market (pr...
2023-03-22 06:30:14 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Stocks with potential are probably not everyone’s cup of tea right now. With talks of an impending recession, everyone is looking for safer options. However, Shelby Davis once famously s...
2023-03-16 10:07:00 ET Exact Sciences (NASDAQ: EXAS) is a cancer diagnostics company with promising long-term potential. Its Cologuard non-invasive test can detect colorectal cancer and help save lives. The company also has tests for other types of cancer as well. Last year, it gene...
2023-03-12 09:15:00 ET Last year, the Nasdaq Composite fell into a bear market and lagged behind the other two major U.S. market indexes. But things could be radically different in 2023. Downturns rarely happen two years in a row, and the tech-heavy index has impressed so far this year....
2023-03-09 08:34:12 ET Following the earnings season, Citi has taken a fresh look at its life science tools & diagnostics coverage, upgrading the colorectal cancer test maker Exact Sciences ( NASDAQ: EXAS ) and downgrading its rival Guardant Health ( NASDAQ: GH ). ...
Cancer test maker Exact Sciences ( NASDAQ: EXAS ) said Friday that two of its convertible debt holders have agreed to accept newly issued convertible senior notes due 2030 in exchange for certain 2025 notes in a privately negotiated transaction. Per the terms, the company has agreed t...
News, Short Squeeze, Breakout and More Instantly...
Exact Sciences Corporation Company Name:
EXAS Stock Symbol:
NASDAQ Market:
Exact Sciences Corporation Website:
2024-07-11 08:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-08 08:30:00 ET To say that Exact Sciences (NASDAQ: EXAS) hasn't performed well on the stock market this year would be an understatement. Shares of the cancer-focused biotech are down by 41%. However, the healthcare company still has some fans on Wall Street. Cathie Wood ...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S. financial markets on July 31, 2024. Following the release, company management w...